# A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-budget-impact-model-for-biosimilar-infliximab-in-crohn-s-disease-in-bulgaria/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Valentin Brodszky,Fanni Rencz,Márta Péntek,Petra Baji,Péter L. Lakatos,László Gulàcsi |
| Citations | 72 |
| DOI | 10.1586/14737167.2015.1067142 |
| Fields | Biochemistry, Genetics and Molecular Biology,Economics, Econometrics and Finance,Immunology and Microbiology |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1752472043 |
| PMID | 26162458 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Fanni Rencz](https://scholariq.org/researchers/fanni-rencz/)

## Paper journal

- [Expert Review of Pharmacoeconomics & Outcomes Research](https://scholariq.org/journals/expert-review-of-pharmacoeconomics-and-outcomes-research/)

## Paper primary topic

- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Paper topics

- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Pharmaceutical Economics and Policy](https://scholariq.org/topics/pharmaceutical-economics-and-policy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.